Semaglutide vs. tirzepatide: how the two actually compare

If you have spent any time reading about weight-loss medication, you have seen the two names side by side, usually with a number attached to each. The comparison is rarely as clean as it looks. Both medicines work, both are prescription-only, and which one is appropriate is a clinical judgment — not a leaderboard.

The shared foundation

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut already releases after eating, and holds that signal steady for days instead of minutes. We covered the mechanism in detail in GLP-1, explained.

Tirzepatide does the same thing — and one more. Alongside GLP-1, it also acts on GIP (glucose-dependent insulinotropic polypeptide), a second incretin hormone involved in how your body handles a meal. That is what “dual-action” refers to, and we unpack it in what tirzepatide does differently.

Why you cannot just compare the headline numbers

This is the part most comparisons get wrong, and it matters more than any single figure.

The widely quoted results for each medicine come from separate trials — the STEP programme for semaglutide, the SURMOUNT programme for tirzepatide. Those trials enrolled different people, ran for different durations, used different dose ladders, and paired the medicine with different levels of lifestyle support. Lining up an average from one against an average from the other is not a comparison; it is two unrelated measurements placed next to each other.

A genuine head-to-head comparison means one trial, one protocol, participants randomly assigned between the two arms. That is a meaningfully harder study to run, and it is the only design that answers “which one is better” with any rigour.

So when you see a confident ranking online, the honest question is: compared under what conditions, in whom, for how long?

What that means for you specifically

Even a perfect head-to-head would tell you about averages across a population, not about you. Two people with the same starting weight can respond differently to the same medicine and dose. Trial averages set expectations; they do not make predictions.

What a physician actually weighs when choosing between them:

• Your medical history, and whether anything in it favours or rules out either option.
• Other medicines you take, and how they interact.
• How you have tolerated treatment before, if you have taken one previously.
• Practical fit — dosing format, and what is sustainable for you over months rather than weeks.
• Cost, honestly. The most effective medicine is the one you can actually stay on.

“Stronger” is not automatically “right”

It is tempting to read a bigger average as a better choice. But tolerability and adherence matter enormously in a treatment measured over months. A medicine that produces more side effects for a particular person, or that they stop taking after eight weeks, does not outperform a gentler option they stay on.

This is also why both medicines start at low doses and climb slowly — see titration, explained. The dose ladder exists precisely because the goal is a medicine you can keep taking.

How the decision actually gets made

At Vive, you do not choose the molecule from a menu. You complete the assessment, a PRC-licensed physician reviews your history and goals, and they recommend what is clinically appropriate — including, sometimes, that neither is right for you. That is the review working as intended.

Results vary from person to person. Both medicines are prescription-only, both carry real contraindications and side effects, and both are used alongside nutrition and activity changes rather than instead of them. Read the Important Safety Information before starting anything.